RBC Capital Maintains Outperform on Pliant Therapeutics, Lowers Price Target to $53
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams has maintained an Outperform rating on Pliant Therapeutics (NASDAQ:PLRX) but reduced the price target from $54 to $53.
November 10, 2023 | 7:24 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
RBC Capital analyst reaffirms Outperform rating on Pliant Therapeutics but lowers price target from $54 to $53.
The reduction in price target is marginal, suggesting a slight adjustment in valuation rather than a significant change in the company's outlook. The Outperform rating indicates continued analyst confidence in the company's prospects, which could balance out the minor negative impact of the price target decrease.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100